BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
Taking everything into account, BRM scores 5 out of 10 in our fundamental rating. BRM was compared to 50 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. Finally BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BRM has a Return On Assets (5.86%) which is in line with its industry peers.
With an excellent Return On Equity value of 31.16%, BRM belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
With a decent Return On Invested Capital value of 13.26%, BRM is doing good in the industry, outperforming 69.23% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 14.77%.
The last Return On Invested Capital (13.26%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROIC | 13.26% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM has a Profit Margin (11.38%) which is comparable to the rest of the industry.
The Operating Margin of BRM (27.11%) is better than 76.92% of its industry peers.
BRM's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 74.69%, BRM is in the better half of the industry, outperforming 71.15% of the companies in the same industry.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BRM is still creating some value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
Compared to 5 years ago, BRM has less shares outstanding
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
BRM has an Altman-Z score of 2.07. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.07, BRM perfoms like the industry average, outperforming 40.38% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.80, which is a good value as it means it would take BRM, 3.80 years of fcf income to pay off all of its debts.
BRM has a Debt to FCF ratio (3.80) which is in line with its industry peers.
A Debt/Equity ratio of 2.67 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a worse Debt to Equity ratio (2.67) than 80.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Altman-Z | 2.07 |
ROIC/WACC1.51
WACC8.77%
2.3 Liquidity
A Current Ratio of 1.28 indicates that BRM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.28, BRM is not doing good in the industry: 61.54% of the companies in the same industry are doing better.
BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 599.05% over the past year.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 4.62%.
Measured over the past years, BRM shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
3.2 Future
BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.74% yearly.
Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -5.02% on average per year.
EPS Next Y483.63%
EPS Next 2Y132.24%
EPS Next 3Y74.73%
EPS Next 5Y36.74%
Revenue Next Year-3.32%
Revenue Next 2Y-5.19%
Revenue Next 3Y-3.73%
Revenue Next 5Y-5.02%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.39, the valuation of BRM can be described as very cheap.
92.31% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (27.41), we can say BRM is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.63, the valuation of BRM can be described as very cheap.
BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 92.31% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.19. BRM is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.39 | ||
| Fwd PE | 7.63 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 88.46% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 94.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.29 | ||
| EV/EBITDA | 6.3 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM's earnings are expected to grow with 74.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y132.24%
EPS Next 3Y74.73%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.11%, BRM is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.00, BRM pays a better dividend. On top of this BRM pays more dividend than 90.38% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.11% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
BRM pays out 90.59% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP90.59%
EPS Next 2Y132.24%
EPS Next 3Y74.73%
FRA:BRM (7/11/2025, 7:00:00 PM)
40.13
-1.13 (-2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.11%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap81.67B
Analysts67.5
Price Target48.82 (21.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.11% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP90.59%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.45%
Min EPS beat(2)13.54%
Max EPS beat(2)19.36%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)13.54%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)11.3%
EPS beat(12)11
Avg EPS beat(12)9.38%
EPS beat(16)15
Avg EPS beat(16)7.79%
Revenue beat(2)2
Avg Revenue beat(2)4.66%
Min Revenue beat(2)3.68%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.59%
Min Revenue beat(4)3.68%
Max Revenue beat(4)5.63%
Revenue beat(8)6
Avg Revenue beat(8)1.95%
Revenue beat(12)8
Avg Revenue beat(12)1.4%
Revenue beat(16)10
Avg Revenue beat(16)1.19%
PT rev (1m)-0.25%
PT rev (3m)-13.71%
EPS NQ rev (1m)-14.44%
EPS NQ rev (3m)-18.85%
EPS NY rev (1m)-4.27%
EPS NY rev (3m)-2.33%
Revenue NQ rev (1m)0.32%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.39 | ||
| Fwd PE | 7.63 | ||
| P/S | 2 | ||
| P/FCF | 7.29 | ||
| P/OCF | 6.67 | ||
| P/B | 5.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.3 |
EPS(TTM)6.28
EY15.65%
EPS(NY)5.26
Fwd EY13.11%
FCF(TTM)5.5
FCFY13.72%
OCF(TTM)6.02
OCFY15%
SpS20.04
BVpS7.31
TBVpS-11.29
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROCE | 18.89% | ||
| ROIC | 13.26% | ||
| ROICexc | 16.01% | ||
| ROICexgc | 72.41% | ||
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% | ||
| FCFM | 27.47% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.98%
ROICexgc(3y)70.34%
ROICexgc(5y)71.31%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Debt/EBITDA | 2.21 | ||
| Cap/Depr | 15.15% | ||
| Cap/Sales | 2.57% | ||
| Interest Coverage | 6.1 | ||
| Cash Conversion | 68.16% | ||
| Profit Quality | 241.48% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.07 |
F-Score7
WACC8.77%
ROIC/WACC1.51
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
EPS Next Y483.63%
EPS Next 2Y132.24%
EPS Next 3Y74.73%
EPS Next 5Y36.74%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
Revenue Next Year-3.32%
Revenue Next 2Y-5.19%
Revenue Next 3Y-3.73%
Revenue Next 5Y-5.02%
EBIT growth 1Y22.52%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year282.44%
EBIT Next 3Y50.39%
EBIT Next 5Y24.24%
FCF growth 1Y18.09%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y17.06%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%